DOPAMINE HYDROCHLORIDE - Generic Drug Details

What are the generic sources for dopamine hydrochloride and what is the scope of patent protection?

Dopamine hydrochloride is the generic ingredient in six branded drugs marketed by Abbott, Abraxis Pharm, Am Regent, Baxter Hlthcare, Hikma Intl Pharms, Hospira, Igi Labs Inc, Intl Medication, Lyphomed, Smith And Nephew, Teligent, Teva Parenteral, Warner Chilcott, and B Braun, and is included in thirty-seven NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for dopamine hydrochloride. Eight suppliers are listed for this compound.

Summary for DOPAMINE HYDROCHLORIDE

US Patents:	0
Tradenames:	6
Applicants:	14
NDAs:	37
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1,100
Patent Applications:	4,281
What excipients (inactive ingredients) are in DOPAMINE HYDROCHLORIDE?	DOPAMINE HYDROCHLORIDE excipients list
DailyMed Link:	DOPAMINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for DOPAMINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Krzysztof Bankiewicz	PHASE1
European Group for Research In Schizophrenia	PHASE3
Medical University of Vienna	NA

See all DOPAMINE HYDROCHLORIDE clinical trials

Pharmacology for DOPAMINE HYDROCHLORIDE

Drug Class

Catecholamine

Medical Subject Heading (MeSH) Categories for DOPAMINE HYDROCHLORIDE

Cardiotonic Agents

Dopamine Agents

Sympathomimetics

Anatomical Therapeutic Chemical (ATC) Classes for DOPAMINE HYDROCHLORIDE

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

US Patents and Regulatory Information for DOPAMINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	DOPAMINE HYDROCHLORIDE	dopamine hydrochloride	INJECTABLE;INJECTION	018132-004	Jul 9, 1982	AP	RX	Yes	Yes
Igi Labs Inc	DOPAMINE HYDROCHLORIDE	dopamine hydrochloride	INJECTABLE;INJECTION	070094-001	Oct 23, 1985		DISCN	No	No
Hikma Intl Pharms	DOPAMINE HYDROCHLORIDE	dopamine hydrochloride	INJECTABLE;INJECTION	207707-001	Apr 11, 2018	AP	RX	No	No
Teligent	DOPAMINE HYDROCHLORIDE	dopamine hydrochloride	INJECTABLE;INJECTION	018656-001	Jun 28, 1983		DISCN	No	No

Market Dynamics and Financial Trajectory for Dopamine Hydrochloride

Last updated: January 24, 2026

Executive Summary

Dopamine Hydrochloride remains a vital therapeutic agent in emergency and critical care settings, primarily for conditions such as shock, heart failure, and acute hypotension. Despite its longstanding clinical application, recent market shifts driven by technological advancements, regulatory frameworks, and emerging therapies influence its demand and financial outlook. This report provides a comprehensive analysis of the current market environment, growth drivers, challenges, and future financial trajectory of dopamine hydrochloride, essential for stakeholders—including manufacturers, investors, and healthcare providers.

---

1. Market Overview

Aspect	Details
Current Global Market Size	Estimated at USD 200–250 million in 2022 (Market Research Future) [1]
Market CAGR (2023–2028)	Approx. 3-4%, reflecting modest growth
Major Regional Markets	North America (45%), Europe (25%), Asia-Pacific (15%), Rest of the World (15%)
Key Segments	Injectable forms (IV solutions), compounded formulations, generic versions

---

2. Market Drivers

Driver	Description	Evidence/Source
Critical Care Usage	High-volume usage in ICU for shock, cardiac failure, hypotension	AHA Guidelines, 2021 [2]
Established Clinical Efficacy	Long-standing therapeutic profile, trusted by clinicians	FDA Drug Approval History
Manufacturing Cost Dynamics	Fragmented production landscape leading to cost stability	Market Reports [3]
Regulatory Approvals and Policies	Supportive policies for essential medicines	WHO Essential Medicines List [4]

3. Market Challenges

Challenge	Impact	Mitigation Strategies
Regulatory Scrutiny & Quality Standards	Stringent manufacturing practices raise barriers and costs	Investment in GMP, QA infrastructure
Emergences of Alternatives	New therapies (e.g., norepinephrine, vasopressin) potentially supplant dopamine use	R&D focus on combination or alternative drugs
Pricing Pressures & Reimbursement Policies	/Shrinking margins in developed markets	Diversification, cost optimization
Limited New Formulation Innovations	Slow innovation pipeline can restrict growth	Focus on novel delivery mechanisms

---

4. Competitive Landscape

Company	Market Share (Estimate)	Key Products/Strengths	Recent Developments
Pfizer	30%	Branded injectable formulations, global distribution	Focus on biosimilar/brand extension initiatives
Sandoz (Novartis)	20%	Generic manufacturing, low-cost production	Price competitiveness initiatives
Teva Pharmaceuticals	15%	Wide distribution network, cost-effective generics	Entry into emerging markets
Others	35%	Regional players, emerging generic labs	Strategic alliances in Asia-Pacific

5. Regulatory Environment Impact

• FDA & EMA Regulations: Strict adherence to GMP standards influences market access and costs.
• WHO Essential Medicine List: Recognizes dopamine hydrochloride as essential, aiding global procurement.
• Generic Drug Policies: Encourage market entry, reducing prices, but also intensify competition.
• Patent & IP Considerations: No recent patent expirations, maintaining generic entry barriers.

---

6. Technological and Clinical Development Trends

Trend	Impact	Future Outlook
Formulation Innovations	Minimal; focus remains on stability and ease of administration	Potential for sustained-release preparations
Combination Therapies	Limited; dopamine used mainly for acute, targeted therapy	R&D exploring adjunct therapies
Automation and Quality Control	Enhances manufacturing efficiency, reduces costs	Industry adoption expected to grow
New Delivery Devices	No significant innovations; standard IV infusion remains dominant	Potential for smart infusion pumps

---

7. Financial Trajectory and Forecast

Year	Market Size (USD Million)	Key Growth Factors	Risks
2023	200–250	Critical care demand steady; generic manufacturing stable	Regulatory delays, market saturation
2024	210–260	Expansion in emerging markets; renewed clinical protocols	Competition, pricing pressures
2025	220–280	Medical infrastructure investments; policies favor essential medicines	Innovation lag, alternative therapies
2026–2028	CAGR 3-4%	Consistent legacy use; cost advantages; emerging markets growth	Potential for substitution by newer agents

8. Comparison with Similar Agents

Drug Class	Main Usage	Market Size (USD) (2022)	Entry Barriers	Innovation Level
Vasopressors (Norepinephrine, Epinephrine)	Shock, cardiac arrest	1.5 billion	Patent protection, R&D intensity	Moderate
Inotropes (Dobutamine)	Heart failure	600 million	Regulatory, clinical trials	Moderate
Vasopressin	Vasoconstriction, shock	350 million	Limited innovation	Low

---

9. Regional Market Dynamics

Region	Market Characteristics	Growth Opportunities
North America	Mature market, high quality standards	Focus on quality, safety, and supply chain optimization
Europe	Similar to North America; price sensitivity	Reimbursement-driven strategies
Asia-Pacific	Rapid growth due to increasing healthcare infrastructure	Low-cost manufacturing, expanding hospital networks
Latin America & Africa	Emerging markets, dependence on imports	Government procurement, e.g., PAHO/WHO tenders

---

10. Future Outlook and Strategic Considerations

• Sustained demand due to the entrenched role in critical care.
• Potential market expansion in emerging economies owing to improved healthcare infrastructure.
• High price competition among generics could exert downward pressure.
• Innovation limited, but opportunities exist in formulation stability and administration technologies.
• Regulatory compliance remains paramount, particularly for quality assurance.
• Risk mitigation involves diversification and potential development of adjunct or combination therapies.

---

Key Takeaways

• Dopamine hydrochloride maintains a steady, if modest, growth trajectory driven by critical care needs.
• The global market is largely saturated, with generic manufacturers dominating due to low innovation barriers.
• Emerging markets and healthcare infrastructure expansion offer growth avenues.
• Competition from alternative vasopressors and inotropes remains a challenge.
• Regulatory adherence and quality control are critical to market access and retention.

---

FAQs

Q1: What are the primary therapeutic uses for dopamine hydrochloride?
A: It is used principally in the management of shock, heart failure, and acute hypotension, functioning as a sympathomimetic agent to increase cardiac output and blood pressure.

Q2: How does the regulatory environment influence market prospects?
A: Regulatory standards, especially GMP compliance mandated by the FDA and EMA, impact manufacturing costs, approval timelines, and market access, while inclusion in the WHO Essential Medicines List facilitates procurement in developing countries.

Q3: Are there innovative developments in dopamine hydrochloride formulations?
A: Currently, innovation is limited. Focus remains on improving stability and infusion delivery methods, with little movement toward novel formulations or delivery systems.

Q4: What are the key competitive strategies for market players?
A: Price competition through generics, ensuring regulatory compliance, expanding into emerging markets, and maintaining high-quality standards are primary strategies.

Q5: What is the outlook for dopamine hydrochloride's market growth?
A: Modest growth at approximately 3-4% CAGR through 2028, primarily driven by economic growth in emerging markets, with continued relevance in critical care settings.

---

References

[1] Market Research Future. Pharmaceutical Market Reports, 2022.
[2] American Heart Association. Guidelines for Shock Management, 2021.
[3] Industry Analysis Report. Generic Pharmaceuticals Market, 2021.
[4] World Health Organization. WHO Model List of Essential Medicines, 2021.